Cellular Signaling and Potential New Treatment Targets in Diabetic Retinopathy by Khan, Zia A. & Chakrabarti, Subrata
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2007, Article ID 31867, 12 pages
doi:10.1155/2007/31867
ReviewArticle
Cellular Signaling and Potential New Treatment Targets in
Diabetic Retinopathy
Zia A. Khan and Subrata Chakrabarti
Received 28 December 2006; Revised 2 May 2007; Accepted 13 September 2007
Recommended by Timothy Kern
Dysfunction and death of microvascular cells and imbalance between the production and the degradation of extracellular matrix
(ECM) proteins are a characteristic feature of diabetic retinopathy (DR). Glucose-induced biochemical alterations in the vascu-
lar endothelial cells may activate a cascade of signaling pathways leading to increased production of ECM proteins and cellular
dysfunction/death. Chronic diabetes leads to the activation of a number of signaling proteins including protein kinase C, pro-
tein kinase B, and mitogen-activated protein kinases. These signaling cascades are activated in response to hyperglycemia-induced
oxidative stress, polyol pathway, and advanced glycation end product formation among others. The aberrant signaling pathways
ultimately lead to activation of transcription factors such as nuclear factor-κB and activating protein-1. The activity of these tran-
scription factors is also regulated by epigenetic mechanisms through transcriptional coactivator p300. These complex signaling
pathways may be involved in glucose-induced alterations of endothelial cell phenotype leading to the production of increased
ECM proteins and vasoactive eﬀector molecules causing functional and structural changes in the microvasculature. Understand-
ing of such mechanistic pathways will help to develop future adjuvant therapies for diabetic retinopathy.
Copyright © 2007 Z. A. Khan and S. Chakrabarti. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Diabeticretinopathy(DR),themostcommoncauseofblind-
ness in the working population, is also the most frequent
manifestation of the diabetic microvascular disease [1, 2].
Nearly all people with type 1 and more than half with
type 2 diabetes develop retinopathy [3]. Retinal complica-
tions in chronic diabetes may culminate from microvascu-
lar dysfunction, neuroglial abnormalities, and metabolic im-
balance including the lack (type 1) or excess (type 2) of in-
sulin. Microvascular alterations comprise of microvascular
endothelial cell (EC) dysfunction, vessel leakage, and occlu-
sions. Clinically, DR can be classiﬁed as nonproliferative DR
(NPDR) and proliferative DR (PDR) [3–7]. NPDR is struc-
turally characterized by capillary basement membrane (BM)
thickening, pericyte loss, microaneurysms, increased perme-
ability, exudate deposits, and retinal microinfarcts [3–7]. Di-
abetic macular edema may lead to signiﬁcant visual impair-
ment in NPDR. Also NPDR has further been divided in pro-
gressive stages: mild, moderate and severe. The later stages
(sometimesalsocalledpreproliferativeretinopathy)showin-
creased retinal damage as evidenced by increased retinal vas-
cular blockage and infarcts. If left untreated, proliferative
retinopathycharacterizedbyabnormalneovascularizationin
the retina develops. The devastating outcome of the prolif-
erative retinopathy is hemorrhage and tractional retinal de-
tachment.
Although it has been customary to consider a common
origin of microvascular disease in both type 1 and type 2 di-
abetes, recent evidence suggests considerable heterogeneity
in the development and progression among the two popula-
tions.Clinicalstudiesrevealthatvisionthreateningretinopa-
thy is usually because of neovascularization in type 1 and
maculopathy in type 2 patients [8, 9]. Clinical trials have
shown that good glycemic control can reduce the develop-
ment of retinopathy in both type 1 [10]a n dt y p e2[ 11] di-
abetic patients. Current treatment for PDR and maculopa-
thy is carried out by laser photocoagulation which prevents
further loss of vision. However, these therapeutic modalities
areineﬀectiveagainstrestoringdiminishedvisualacuity.Un-
derstanding the molecular basis of DR pathogenesis may of-
fer better therapeutic regimens. Towards this aim, investiga-
tors have studied the eﬀects of high glucose levels in animal
models of the disease and cultured cells. These in vivo and in
vitro models do not fully recapitulate the disease process ob-
served in humans. The proliferative stage of the DR has not
been observed in the well studied rodent models. However,
both the in vitro and the in vivo models do oﬀer insight into2 Experimental Diabetes Research
the early molecular changes which may dictate the more ad-
vanced stages of the disease. This review will highlight some
of these ﬁndings in both cultured vascular ECs and animal
modelsofdiabeteswithanemphasisoncellsignalingandthe
early molecular changes mediating microvascular alterations
in DR.
2. STRUCTURAL AND FUNCTIONAL
CHANGES IN DR
2.1. Alterationofvasoactiveeffectormolecules
Vasoactive eﬀector molecules play important roles in both
early and late stages of DR. Hyperglycemia leads to increased
vasoconstriction and impaired endothelium-dependent va-
sodilation [12–20]. Increased expression of endothelin-1
(ET-1), the most potent vasoconstrictor, has been shown
in diabetes (reviewed in [13]). Increased ET-1 mediates
vasoconstriction in the retina which is readily prevented
by inhibiting ET receptor signaling [19]. In cultured cells,
we have also shown that ET-1 increases EC permeability
and extracellular matrix (ECM) protein expression [13, 21–
23] possibly through protein kinase C (PKC) activation
[24].
Endothelium-dependent vasodilatory responses have
been shown to be dampened in diabetics [14–18]. Data ac-
cumulated to date indicates increased levels of endothelial
(e-) and inducible (i-) nitric oxide synthase (NOS) enzymes
in response to high levels of glucose [25, 26]. Such a phe-
nomenon is also evident in animal and human diabetes (re-
viewed in [27]). In addition, a number of molecular path-
ways which are altered in diabetes may increase the activity
of NOS enzymes; these include vascular endothelial growth
factor (VEGF) [28], and PKC and protein kinase B signal-
ing pathways [28–30]. A few theories can be formulated to
account for the discrepancy between increased NOS expres-
sion/activity, NO levels and impaired vasodilation. Increased
NO production but decreased bioavailability may be one ex-
planation. Secondly, ET-induced vasoconstriction may over-
whelm the vasodilatory action of NO. In the context of di-
abetic milieu (increased ET levels and oxidative stress), NO
may also mediate other cellular activities such as EC prolif-
eration as suggested by the increased NO level observed dur-
ing the proliferative phase of DR. Finally, NO function may
be inﬂuenced by heme oxygenase-1 (HO-1) [25]. We have
shown that diabetes causes oxidative DNA damage in several
tissues including the retina and alter blood ﬂow through the
induction of HO-1 [25, 27, 31]. HO-1 agonist in ECs and
animals mimics the eﬀects of high glucose and diabetes by
increasing NOS levels.
Anextensiveinteractionexistsamongthesevasoactiveef-
fectormoleculeswhichdeterminetheexpression/production
and function of the respective molecule [13, 26]. Taken to-
gether, these studies have shown that alteration of these va-
soactive eﬀector molecules may be instrumental in the pro-
duction of early changes in DR such as blood ﬂow alter-
ations, increased permeability, and ECM deposition, even-
tually leading to nonperfusion of the retinal tissue.
2.2. Cellulardysfunctionanddeath—effecton
retinalvascularfunction
One early event in DR is the loss of pericytes from capillaries
and venules [32, 33]. Pericyte loss is believed to contribute
to the earliest clinically visible manifestation of DR, microa-
neurysms [34]. This loss may occur due to increased oxida-
tive stress, toxicity from high levels of glucose, and other fac-
tors. Recently, autoantibodies against pericytes have been de-
tected in the sera of diabetic patients [35, 36]. Loss of peri-
cytes may not only aﬀect the vascular tone but may also lead
to EC phenotypical changes. The integral communication
between ECs and contractile cells of the vascular wall is in-
creasing being realized (for review, see [37–39]). In addition
to the indirect role of pericytes in producing EC dysfunction,
high levels of glucose may directly lead to EC damage and
loss [13, 26, 40].
Retinal ﬂuorescein angiography has revealed areas of
nonperfusion in DR [41, 42]. Comparing the results from
these studies with retinal digest experiments [43, 44], it is
evident that most nonperfused areas in the retina have de-
generative pericytes and ECs. These ﬁndings may suggest
that retinal vascular perfusion is dependent on intact en-
dothelium [45, 46]. Although numerous studies can be cited
which demonstrate abnormal platelet function in diabetes,
attempts to modify the function have produced much dis-
appointment (reviewed in [47]). Platelets isolated from dia-
beticanimalswereshowntobemoreadherenttothediabetic
vasculature than platelets from nondiabetic animals [48].
Thrombocytopenia produced by administering antiplatelet
serum caused further retinal blood barrier breakdown [48].
However, assessing other features of DR has revealed no
beneﬁcial or deleterious eﬀects of selective antiplatelet drug
clopidogrel [49]. These ﬁndings indicate that the platelet
function may be altered in diabetes; however, the exact role
played by the platelets is not clear. More recently, leukocytes
were shown to adhere to retinal vasculature [50]andmediate
capillary occlusion in streptozotocin-induced diabetic rats
[51]. The levels of adhesion molecules (ICAM and VCAM)
as assessed by nonquantitative immunohistochemical tech-
niques were shown to be increased or unchanged [52, 53].
Soluble forms of these adhesion molecules have been re-
ported to be higher in the vitreous of patients with PDR
[54]. Furthermore, exposure of ECs to either tumor necro-
sis factor-α or advanced glycation end products increases the
expression of VCAM [55] providing a mechanistic basis in
diabetes.
Sustained hyperglycemia is related to increased vascular
permeability [56, 57]. Permeability studies in type 1 and hy-
pertensive type 2 diabetic patients have revealed increased
albumin ﬂux through the endothelium [58–65]. The direct
cellular and molecular mechanism is still obscure; in part,
due to our inability to adequately assess vascular permeabil-
ityunambiguously.Inculturedcells,however,wehaveshown
that glucose- and ET-1 induced EC permeability can be nor-
malized by PKC inhibition [24]. It is believed that a dys-
function in the transfer property of the endothelium occurs,
which when precipitated with occlusion, leads to under- or
nonperfusion. These areas of nonperfusion, in conjunctionZ. A. Khan and S. Chakrabarti 3
with cellular damage, may trigger a reparative response; a
ﬁnding well documented in retinal microcirculation [40].
2.3. Capillarybasementmembrane(BM)thickening
A consistent feature of DR is thickening of the capillary
BMs [66–71]. Capillary BM thickening can result from in-
creased production and decreased degradation of the extra-
cellular matrix (ECM) proteins [67, 69]. High levels of glu-
cose (30mM) can increase mRNA expression of ECM pro-
teins, collagen and ﬁbronectin (FN), in the kidney mesan-
gial cells and the retinal ECs [72–74]. Retinal BMs of dia-
betic animals have been shown to contain increased collagen
α1( I V ) ,a n dβ1a n dγ chains of laminin, and FN [75]. These
changes are brought upon as early as 8 weeks following onset
of diabetes [75]. We have also shown that diabetes increases
ECM protein expression in the kidney, retina, and heart of
streptozotocin-induced diabetic rats [21, 76, 77]. In addition
to collagen α1 (IV) and FN, upregulation of other ECM pro-
teins such as tenascin has been found in retinal vessels of di-
abetic patients and animals [78, 79]. However, no diﬀerence
has been shown in the amount of proteoglycans in BMs of
patients with DR [80].
Recently, we have demonstrated that FN undergoes alter-
ativesplicinginDRtoproduceanembryonicisoformED-B+
FN (oncofetal FN) [81]. Increased levels of this isoform are
evidentinvitreousofpatientswithPDRandretinaltissuesof
diabeticrats.Thisisoformisnormallyabsentinnormaladult
tissues and may be involved in functional eﬀects via outside-
in signaling [22]. In cultured vascular ECs, we have shown
that ED-B+ FN is involved in VEGF expression and EC pro-
liferation suggesting an important role of this FN isoform in
DR.
3. MOLECULAR MECHANISMS OF DR PATHOGENESIS
DR is a culmination of numerous biochemical alterations
which take place in the vascular tissue of the retina. High lev-
els of glucose aﬀect both the vascular ECs and the pericytes.
The retinal ECs incorporate glucose via glucose transporter-
1 induced facilitative diﬀusion [82–84]. Therefore, increased
circulatinglevelsofglucoseaccumulateintheretinalECsand
lead to activation of various biochemical pathways. It is pos-
siblethatotherfactors,suchashyperinsulinemiaanddyslipi-
demia, may also contribute to the abnormal signaling in DR.
In this review, we will explore the diabetes-induced molecu-
lar alterations in the retina and glucose-induced changes in
cultured ECs in an attempt to identify novel therapeutic tar-
gets for DR.
3.1. Aldosereductase(AR)andthepolyolpathway
Hyperglycemia-inducedsecondarycomplicationsofdiabetes
are particularly evident in tissues which are not insulin-
sensitive such as the retinal vasculature. Under normal con-
ditions,glucoseutilizationisprimarilythroughtheglycolytic
pathway. However, in diabetes excessive glucose is metabo-
lized by the polyol pathway/aldose reductase (AR) enzyme.
IncreasedARactivityisimplicatedinthedevelopmentofsec-
ondarydiabeticcomplications[85,86].Glucoseﬂuxthrough
the polyol/AR pathway may lead to sorbitol accumulation
[86] and accompanying cellular damage [86, 87] which may
be prevented by myo-inositol supplementation [88]. It is be-
lieved that increased NADH production, a cofactor for glyc-
eraldehyde 3-phosphate dehydrogenase, leads to augmented
levels of glyceraldehyde 3-phosphate. Thus, polyol pathway
may also contribute to advanced glycation end product for-
mation through methylglyoxal from increased glyceraldehy-
des 3-phosphate [89].
Supplementing these experimental evidences of the in-
volvement of AR enzyme in diabetic complications, clinical
studies show that polymorphisms in AR gene are linked to
increased susceptibility of microvascular complications [90–
92]. Clinical trials to assess AR inhibition as a therapeutic
modality have not shown any conclusive results. One recent
trialwithARinhibitorsorbinilshowedslowerrateofmicroa-
neurysms in the retina [93] .R e c e n t l y ,h o w ev e r ,an e wc l a s so f
AR inhibitors was tested in streptozotocin-induced diabetic
rats [94]. This selective inhibitor, ARI-809, was as eﬀective in
AR inhibition in the animal model as sorbinil. Whether ARI-
809 produces more favorable results in clinical trials remains
to be determined.
3.2. Oxidativestress
Oxidative stress early in the disease state may contribute to
EC dysfunction and may also be the driving force in the
continued insult to the retinal vasculature during the later
stages of the disease. The mechanisms which may underlie
increased oxidative stress in ECs and retinal tissues in dia-
betes are complex and interconnected (Figure 1)[ 26]. The
early pathways of oxidative stress, which may initiate the EC
dysfunction and pave the path for continued vascular dam-
age, include glucose auto-oxidation and mitochondrial su-
peroxide production [95–97]. Inhibiting mitochondrial su-
peroxide production has been shown to be beneﬁcial for DR
[97].
Oxidative stress in diabetes may also be induced by in-
direct means, which include the NADPH oxidase enyzme
[98, 99]. NADPH oxidase may increase superoxide produc-
tion and through induction of xanthine oxidase may also in-
hibit superoxide dismutase. Impairment of antioxidant en-
zymes could also be carried out by increased AR activity
through the imbalance between NADP+/NADPH. A num-
ber of other enzymes have also emerged as being impor-
tantmediatorsofincreasedoxidativestress.Lipoxygenaseen-
zyme (LOX) may also contribute to diabetes-induced oxida-
tive stress. LOX increases oxidation of low density lipopro-
teins (ox-LDLs) [100, 101]. We have shown that glucose in-
creases CD36 (an ox-LDL receptor) and leads to increased
uptake of ox-LDL and oxidative DNA damage in vascular
ECs [100].
Recently, several investigators have shown a role of poly
(ADP-ribose) polymerase (PARP) in cultured ECs and retina
of diabetic animals [102–104]. Increased PARP activity, pos-
sibly in response to oxidative DNA damage, may directly
cause vascular EC dysfunction via the depletion of NAD+
and ATP. PARP may also cause nuclear factor-κB( N F - κB)4 Experimental Diabetes Research
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Figure 1:Mechanismandconsequenceofincreasedoxidativestress
in DR (NADPH, nicotinamide adenine dinucleotide phosphate;
AR, aldose reductase; LOX, lipoxygenase; PARP, poly(ADP-ribose)
polymerase; AGE, advanced glycation end product; RAGE, receptor
for AGE; iNOS, inducible nitric oxide synthase).
activation [105]. In a nondiabetic system, a relationship be-
tween PARP activation, histone deacetylases (HDACs) and
transcription coactivator p300 has been shown [106, 107].
Whether a similar pathway may also be involved in DR re-
quires further investigation.
3.3. Proteinglycation
Protein modiﬁcation has also been shown to play an impor-
tant role in diabetic complications. Glucose may participate
in nonenzymatic glycation of proteins to produce advanced
glycation end products (AGEs) [108, 109]. Both AGEs and
AGE receptors (termed RAGEs) have been localized to the
retinalvasculatureandvascularECs[110–113].Althoughthe
means by which AGE/RAGE cause cellular dysfunction are
currently being elucidated. It is believed that AGEs may lead
to altered protein function, interfere with the ECM function,
and cause elaboration of cytokines. In cultured ECs, AGE
formation has been reported to regulate thrombomodulin,
ET-1, VEGF, and basic-ﬁbroblast growth factor [114–116].
Administration of exogenous AGEs to diabetic animals show
retinal pericyte loss [117]. Retinal ECs, however, proliferate
in response to glycated BMs [118]. These studies provide in-
sightintothemechanismofpericytelossandunregulatedEC
proliferation in the later stages of the disease. Experimental
studies in diabetic animals show that a speciﬁc inhibitor of
nonenzymatic glycation, aminoguanidine, can prevent reti-
nal microaneurysms, acellular capillaries, and pericyte loss
in the diabetic dogs [119].
3.4. ProteinkinaseC(PKC)activation
Exposure of cultured ECs to high levels of glucose leads to
rapid induction of a number of protein kinase family mem-
bers[23,24,120,121]suggestingthattheseproteinsmayplay
a role in transducing the adverse eﬀects of hyperglycemia in
the retinal vasculature. Several studies have shown the acti-
vation of an important protein kinase, PKC [122] in the con-
text of diabetes [23, 24, 122–124]. PKC isoforms which show
signiﬁcant activation in animal models of chronic diabetes
include PKCα, βI, βII, γ,a n dδ [125, 126]. However, PKCβI
and II show the highest level of induction in the retina as
well as the heart and aorta of the diabetic animals [126]. The
mechanism of PKC activation may involve increased diacyl-
glycerol (DAG) levels which have been shown in the retina
of diabetic animals [127] and vascular cells exposed to high
g l u c o s el e v e l s[ 126, 127]. DAG can be increased through the
hydrolysis of phosphatidylinosities or through de novo syn-
thesis. Fatty acid composition analysis of DAG reveal that
the major contributor to increased DAG in hyperglycemic
conditions may be the de novo synthesis or phospholipase-
D mediated production of DAG [127, 128]. PKC activation,
either directly or through interaction with other intracellu-
lar signaling proteins, may cause a number of vascular eﬀects
which are summarized in Figure 2. We and others have pre-
viously shown that PKC may mediate glucose-induced EC
permeability [24, 129] ,a n dE C Mp r o t e i np r o d u c t i o n[ 23].
In addition, PKC may be involved in the expression of vari-
ous growth factors and vasoactive factors, and regulate cel-
lular activity [122, 124, 129–131]. A tremendous amount
of work has also been done on the activation of PKC sec-
ondary to alteration of growth factors and cytokines. One
of the best examples is the activation of PKC through VEGF
which is highly relevant to DR. VEGF mediates cellular sig-
naling in ECs through binding to VEGF receptors (VEGF-
R1 and VEGF-R2). Upon binding of VEGF, VEGF-Rs signal
the release of DAG (through glycolytic pathway intermedi-
ates) [132]. This DAG increase causes activation of selective
PKC isoforms (predominantly β isoform) and mediates the
vasoregulatory role of VEGF such as permeability [133]. In-
vitreal injection of VEGF rapidly increases PKC activation
in the retina. Furthermore, the VEGF-mediated retinal per-
meability can be normalized with PKC-β inhibition [133].
We have shown a similar interaction between PKC and ET-1
[24]. Several experimental and clinical studies have been car-
ried out with selective PKCβ inhibitor, ruboxistaurin mesy-
late (LY333531) [133–138]. In phase III clinical trials rubox-
istaurin showed a delay in the occurrence of moderate visual
loss in patients with NPDR at 24 months [139].
4. EMERGING TARGETS
4.1. Mitogen-activatedproteinkinase(MAPK)
PKC may also regulate the vascular function in chronic di-
abetes through interaction with other signaling complexes
in the vascular ECs. Recently, studies have reported an im-
portant role of MAPK pathway in the diabetic complications
[140, 141] which may, in part, be dependent upon PKC ac-
tivation [23]. MAPK family consists of extracellular signal-
regulated kinase (ERK) and stress- activated components,
namely c-jun N-terminal kinase (JNK) and p38 (for re-
view, see [140, 142]). MAPK activation proceeds through se-
quential activation of MAPKKK, MAPKK, and MAPK [142].
We have shown that glucose-induced ECM protein synthe-
sis in ECs may be mediated by the activation of MAPKZ. A. Khan and S. Chakrabarti 5
Glucose
PKC
Indirect eﬀects Direct eﬀects
Cell-cell contact/permeability
Vasoregulation
Cell growth and proliferation
ECM protein synthesis
MAPK activation
ET-1 induction
Growth factor expression
Figure 2: Role of PKC in vascular function in diabetes (DAG,
diacylglycerol; PKC, protein kinase C; ECM, extracellular matrix;
MAPK, mitogen-activated protein kinase; and ET-1, endothelin-1).
[23]. We have further demonstrated that such MAPK phos-
phorylation leads to activation of transcription factors NF-
κB and activating protein-1 (AP-1) [23]. Inhibition of ei-
ther MAPK or PKC is able to normalize the eﬀects of high
levels of glucose. Furthermore, inhibiting PKC in cells ex-
posed to high glucose reduces MAPK activation suggest-
ing an important cross-regulation between PKC and MAPK.
ECM protein expression through MAPK activation has also
been reported in renal tubular cells [143]i m p l i c a t i n gar o l e
of MAPK in diabetic nephropathy as well [144]. It is, how-
ever, possible that MAPK activation may also occur via a
PKC-independent pathway [145]. Oxidative stress may cause
alternate MAPK activation via ERK5 (big MAPK1/BMK1)
[146]. BMK1 knockout results in angiogenic defect and em-
bryonic lethality [147] .B M K 1 ,h o w e v e r ,d i ﬀers from other
MAPK as it contains a transcriptional activation domain,
mediating protein-protein interaction with several other fac-
tors [147, 148]. Whether such pathways are also activated in
diabetes remains to be determined.
4.2. Activationofotherproteinkinases
Mostrecentdevelopmentsintheattempttoelucidatethesig-
naling events in cultured ECs challenged with high levels of
glucose have revealed a role of signiﬁcantly homologous pro-
tein kinase family members, protein kinase B (PKB), [120]
and serum- and glucocorticoid-regulated kinase-1 (SGK-1)
[121]. Several growth factors stimulate the recruitment of
lipid kinases known as Class I phosphoinositide 3-kinases
(PI3-kinase) to the plasma membrane. These kinases then
phosphorylate the glycerophospholipid phosphatidylinosi-
tol 4,5-bisphosphate (PtdIns(4,5) P2) converting it to Pt-
dIns(3,4,5)P3 (reviewed in [149, 150]). Evidence indicates
that serine/threonine protein kinase PKB may be the key me-
diator of several downstream events regulated by PI3-kinase.
There are three major PKB isoforms α, β, γ. These isoforms
belong to a subfamily of protein kinases named AGC pro-
tein kinases and include PKC and PKA. Following activa-
tion of PI3-kinase, PKB isoforms are recruited to the plasma
membrane and are phosphorylated by phosphoinositide-
dependent kinase 1 (PDK-1). PKB can regulate the function
ofcytoplasmicaswellasnuclearproteins[149,150].Wehave
demonstrated glucose-induced early activation of PKB [120]
and SGK-1 [121]. Inhibiting PKB and SGK-1 either by dom-
inant negative transfections and/or small interfering RNA
causes complete normalization of high glucose-induced FN
expressioninthevascularECs.ThisroleofPKBinECMpro-
tein expression is regulated by both MAPK and PKC [120].
We have further shown that PKB phosphorylation can lead
to the activation of NF-κB and AP-1 [120].
4.3. Transcriptionfactors
All extracellular and intracellular signals converge on tran-
scription factors to regulate various aspects of vascular func-
tionindiabetes.Twoofthemajortranscriptionfactorswhich
have been shown to be instrumental in mediating the eﬀects
of diabetes are NF-κB and AP-1. In nonstimulated cells, NF-
κB exists as a latent dimer in the cytoplasm being bound
to IκB, an inhibitor protein. Upon stimulation, IκB kinase
(IKK) is activated and leads to phosphorylation and subse-
quentdegradationofIκB.WithouttheinhibitoryIκB,NF-κB
translocates to nucleus and aﬀects gene expression by bind-
ing to κB elements in their promoter region [151]. Oxida-
tive stress is one of the main activators of NF-κB[ 151]. In-
terestingly, glucose-induced ET-1 expression may be regu-
lated via NF-κBa c t i v a t i o n[ 152]. Studies have indicated nu-
clear NF-κB immunoreactivity in the pericytes but not reti-
nal vessel ECs of human diabetic eyes [153]. Experimental
evidence in diabetic animals, however, shows NF-κBa c t i v i t y
in retinal vessel ECs [105, 154–156]. Furthermore, ECs cul-
turedin25–30mMglucosealsoshowincreasedNF-κBacti v-
ity [104, 105, 135, 157]. Whether the apparent discrepancy is
due to the species diﬀerence or a result of experimental con-
ditions remains to be determined.
Transcription factor proteins that form the AP-1 dimers
are also activated by multiple stimuli mediating several func-
tions [158]. These proteins include the Jun, Fos, and ATF
subgroups of transcription factors proteins [158, 159]. Hy-
perglycemia activates both NF-κB and AP-1 transcription
factors via multiple pathways. We have recently shown that
MAPK-mediated ECM protein synthesis in ECs is dependent
on both NF-κB and AP-1 activation [23]. ET-1 also increases
FN expression through the activation of these transcription
factors in cultured ECs and target organs of diabetic compli-
cations, retina, kidney, and heart [21, 157]. NF-κB is also a
redox-sensitive transcription factor which is activated by in-
creased oxidative stress and AGE formation [55, 112, 160].
Several other transcription factors may play regulatory role
in these pathways. Recently, a number of clinical trials have
shown some promise for the use of triamcinolone acetonide
in the management of DR (reviewed in [161]). Triamci-
nolone acetonide, a synthetic glucocorticoid, has been re-
ported to reduce vascular permeability, hemorrhages, and
neovascularization in DR. In addition to regulating VEGF,
the mechanisms of action may involve transrepression of6 Experimental Diabetes Research
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Figure 3: Putative signaling mechanisms in vascular ECs and pos-
sible treatment targets for DR (? = hypothetical;   = potential ther-
apeutic target, PARP = poly(ADP-ribose) polymerase; AGE = ad-
vanced glycation end product, PKC = protein kinase C; PKB =
protein kinase B, ECM = extracellular matrix; MAPK = mitogen-
activatedproteinkinase,Ox=oxidativestress,BMK1=bigMAPK1,
HDAC = histone deacetylase).
both NF-κB and AP-1 [147, 162, 163]. Inactive glucocorti-
coid receptors are present in the cytoplasm being bound to
heat shock protein hsp90 which prevents nuclear translo-
cation. Upon ligand binding (steroid/glucocorticoid), hsp90
dissociates and the receptor/ligand complex translocates to
the nucleus. The repression of NF-κB and AP-1 by the gluco-
corticoid receptors is believed to be due to direct interaction
of the receptor with the transcription factors.
4.4. Transcriptioncoactivators
Histone-dependent packaging of the genomic DNA is a key
mechanism in gene regulation. Remodelling of the chro-
matin in the nucleus, regulated by acetylation and deacety-
lation of histone residues, is important in allowing access of
transcription factors for DNA binding. Acting in opposing
manner, histone acetyl transferases (HATs) and histone de-
cetylases (HDACs) control several cellular processes through
transcription factors [164]. p300 and related CREB binding
protein (CBP) are the best characterized HATs. p300 asso-
ciates with CBP associated factor (PCAF) and plays a cru-
cial role in cell diﬀerentiation, growth, and apoptosis [164].
Transcription factors such as NF-κB remain inactive, even
after nuclear translocation, without association with p300
[164, 165]. NF-κB activity in diabetes is regulated by p300.
WehaveshownthatFNexpression,inbothculturedECsand
in the retina of diabetic rats, is mediated by p300 induction
[104]. It is not clear yet whether HDACs may modulate such
pathways. This signaling pathway is modiﬁable through pro-
tein kinase C, protein kinase B, and possible MAPK [104].
These results suggest that diabetes-induced molecular alter-
ations, oxidative stress, PKC and MAPK activation may con-
verge on NF-κB to mediate increased ECM protein expres-
sion in the vascular tissue.
5. CONCLUDING REMARKS
Diabetes leads to selective damage to a number of target
organs including the retina. Studies have identiﬁed com-
mon signaling pathways in cultured cells and animal mod-
els of diabetes which may in concert lead to the patho-
genetic changes in the retinal vasculature. One recurring
theme in DR and other complications of diabetes is vas-
cular EC dysfunction. This endotheliopathy is carried out
by hyperglycemia-induced changes in vasoregulation (ET-
1/NO), oxidative stress, and increased polyol pathway. Al-
tered EC function then is precipitated with continued acti-
vation of intracellular signaling proteins such as PKC, PKB,
and MAPK, ﬁnally culminating in pathological induction of
transcription factors such as NF-κB and AP-1. HATs such as
p300 may represent upstream regulators of these transcrip-
tion factors. The concept of such epigenetic regulation of
gene transcription is intriguing. One integral question in ad-
equate combat of the secondary complications of diabetes is
how does one inhibit such a complex and interrelated sig-
naling cascade? A possible avenue is to identify a point of
convergence which may reside at the epigenetic level. The
activity (including the speciﬁcity) of transcription factors is
also dependent on the coactivators in the protein complex.
A further grasp of the hyperglycemia-induced transcription
machinery (transcription proﬁling) is crucial to identifying
the molecular signature of DR. Future advances in EC biol-
ogy would greatly enhance our ability to simultaneously in-
hibit these signaling proteins, and prevent and possibly re-
verse the adverse eﬀects of chronic diabetes. An outline of
the discussed signaling mechanisms and potential treatment
targets is shown in Figure 3.
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